ISSN: 1351-8216

Journal Home

Journal Guideline

Haemophilia Q1 Unclaimed

Wiley-Blackwell Publishing Ltd United Kingdom

Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Haemophilia is a journal indexed in SJR in Medicine (miscellaneous) and Hematology with an H index of 104. It has a price of 2083 €. It has an SJR impact factor of 1,316 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,316.

Haemophilia focuses its scope in these topics and keywords: haemophilia, haemophilic, musculoskeletal, exercise, therapy, insurance, life, males, methodology, pain, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Categories: Genetics (clinical) (Q1) Hematology (Q1) Medicine (miscellaneous) (Q1)

Price

2083 €

Inmediate OA

NPD

Embargoed OA

0 €

Non OA

Metrics

1,316

SJR Impact factor

104

H Index

213

Total Docs (Last Year)

721

Total Docs (3 years)

5580

Total Refs

2038

Total Cites (3 years)

505

Citable Docs (3 years)

2.38

Cites/Doc (2 years)

26.2

Ref/Doc

Comments

No comments ... Be the first to comment!

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID *

* The email or ORCID field is only to validate the authenticity of the comment, the identity will not be public. .

Other journals with similar parameters

Nature Biomedical Engineering Q1
Journal of Thoracic Oncology Q1
Annual Review of Clinical Psychology Q1
Lancet Digital Health, The Q1
Journal of Experimental Medicine Q1

Compare this journals

Aims and Scope

Best articles by citations

Other national models

A case-control study on the psychological aspects and coping in haemophilic patients

Scientific papers: on the need of structured abstracts, and explicit reporting of levels of evidence and author contributions

Excision of a haeophilic pseudotumour of the ilium, complicated by fistulation

Development and validation of a measure of disease-specific quality of life in young children with haemophilia

The purchaser's dilemma

Additional data on the morbidity of central venous access devices in patients with Haemophilia

West Nile Virus inactivation by the solvent/detergent steps of the second and third generation manufacturing processes for B-domain deleted recombinant factor VIII

The surgical treatment of a haeophilic pseudotumour in an extremity: a report of three cases with pathological fractures

Penetrating injury to the heart in a patient with haemophilia

FDA Workshop on factor VIII inhibitors held at the NIH, Bethesda, MA on 21 November 2003

Recurrent haemoperitoneum in a female patient with type III von Willebrand's disease responded to administration of oral contraceptive

SHOW MORE ARTICLES

The doctor's dilemma

The World Federation of Hemophilia's third global forum on the Safety and Supply of Hemophilia Treatment Products, 22-23 September 2003, Budapest, Hungary

World Federation of Hemophilia Developing World Programmes

Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis - another rebuttal

Particularly 'expensive cases'

The changing patterns of factor VIII (FVIII) and factor IX (FIX) clotting factor usage in a comprehensive care centre between 1980 and 1994

Linkage analysis in haemophilia A: simultaneous genotyping of two polymorphisms of the human factor VIII gene using induced heteroduplex formation

Is there a 'Basque' profile regarding autosomal recessive deficiencies of coagulation factors?*

Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis

Continuous infusion of porcine factor VIII: stability, microbiological safety and clinical experience

Quality of life assessment in haemophilia

Postoperative hepatic laceration in a child with Type 3 von Willebrand disease